FDA Approves Selpercatinib for Lung & Thyroid Cancers with RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for the following indications:
Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC);
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy;
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
In Person Conference & ConventionJuly 18, 2026 at 3:30 PM CDT5005 Glumack Drive, Minneapolis, MN, USAInterContinental Hotel Minneapolis – St. Paul Airport, Minneapolis
In Person Conference & ConventionAugust 12, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI 96825, USARoy's Restaurants – Hawaii Kai, Honolulu
LOS 2026 Cancer Congress - National Oncology Updates
In Person Conference & ConventionAugust 14, 2026 at 11:00 AM CDT859 Convention Center Blvd, New Orleans, LA, USANew Orleans Marriott Warehouse Art District, New Orleans
